Win Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Win Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,922	Closed	-$212K	–	85
2025 Q4	$212K	Buy	+3,922	New	+$189K	0.09%	70

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Win Advisors's BMY Position: Q1 2026 in Review

Win Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 3,922 shares — an estimated $212K sold.

Win Advisors first reported a position in BMY in Q4 2025 and held it in 1 quarter. The position peaked at $212K in Q4 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Win Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Win Advisors sold 3,922 Bristol-Myers Squibb shares in Q1 2026, an estimated $212K.
Win Advisors first reported a position in Bristol-Myers Squibb in Q4 2025 and held it in 1 quarter.
Win Advisors's Bristol-Myers Squibb position peaked at $212K in Q4 2025.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Win Advisors's 13F filing for Q1 2026, filed 1 May 2026.